CA Patent

CA3261510A1 — Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies

Assigned to F Hoffmann La Roche AG · Expires 2024-01-25 · 2y expired

What this patent protects

Patent listed against Inlyta.

Drugs covered by this patent

Patent Metadata

Patent number
CA3261510A1
Jurisdiction
CA
Classification
—
Expires
2024-01-25
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.